«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

28卷

期数:

2022年04期

页码:

383-389

栏目:

基础医学

出版日期:

2022-07-20

文章信息/Info

Title:

Analyze the expression and clinical significance of MED19 gene in hepatocellular carcinoma based on TCGA database

文章编号:

1006-8147（2022）04-0383-07

作者:

武燕洁; 李譞媛; 宣成昊; 兰蓓

（天津医科大学基础医学院生物化学与分子生物学系，天津300070）

Author(s):

WU Yan-jie; LI Xuan-yuan; XUAN Cheng-hao; LAN Bei

（Department of Biochemistry and Molecular Biology，School of Basic Medical Sciences，Tianjin Medical University，Tianjin 300070，China）

关键词:

TCGA; 肝癌; MED19; 基因表达分析

Keywords:

TCGA database; hepatocellular carcinoma; MED19; gene expression analysis

分类号:

R735.7

DOI:

-

文献标志码:

A

摘要:

目的：探讨MED19在肝癌患者中的表达及与预后的关系。方法：基于TCGA数据库收集相关数据，挖掘MED19在肝癌组织和正常组织、不同临床特征和免疫分型中的表达差异。比较MED19在免疫分型中的表达差异，并基于“ESTIMATE”算法分析其表达水平与肿瘤微环境的相关性。通过Kaplan-Meier法以及Cox回归分析MED19表达量对肝癌患者生存期的影响。通过基因集富集分析（GSEA）并且筛选差异基因进行基因本体（GO）和京都基因与基因组百科全书（KEGG）富集分析，探讨MED19的表达对其他基因集的影响。利用Cellminer数据库数据分析MED19表达量与药物敏感性的关系。结果：在肿瘤组织中MED19的表达增加（W=1 422，P＜0.001），且MED19表达量与临床分期（stage Ⅱ vs. stage I：W=5 828，P＜0.01，stage Ⅲ vs. stage I，W=5707，P＜0.01）、病理分级（G3 vs. G1：W=2 656，P＜0.05）和T分期（T2 vs. T1：W=6 485，P＜0.01，T3 vs. T1：W=5 758，P＜0.01，T4 vs. T1：W=770，P＜0.05）相关。不同免疫亚型中MED19的表达存在差异，且MED19高表达引起基质得分减少（W=14 363，P＜0.01）。MED19高表达使肝癌患者生存率下降（χ2=11.7，P＜0.01），且是患者生存的独立危险因素（HR=1.123，P＜0.01）。GSEA结果显示MDE19高表达组在癌症相关通路富集，此外MED19高表达组和低表达组差异基因的GO和KEGG分析表明，MED19高表达组中的上调表达基因也主要在细胞周期等相关通路富集。药物敏感性分析显示MED19在癌症中高表达与克拉屈滨（r=0.331，t=2.671，P=0.010）、白屈菜红碱（r=0.313，t=2.507，P=0.015）等药物的敏感性呈正相关。结论：MED19在肝癌中表达升高，且与肝癌的预后不良相关。

Abstract:

Objective： To investigate the expression and prognosis of MED19 in patients with hepatocellular carcinoma （HCC）. Methods: Relevant data were collected based on TCGA database to explore the expression differences of MED19 in immune types between HCC tissues and normal tissues，as well as in different clinical characteristics. The expression differences of MED19 in immune types were compared，and the correlation between the expression level of MED19 and tumor microenvironment was analyzed based on "ESTIMATE" algorithm. Kaplan-Meier method and Cox regression were used to analyze the influence of MED19 expression level on the survival of HCC patients. Gene set enrichment analysis（GSEA），Gene Ontology（GO） and Kyoto Encyclopedia of Genes and Genomes （KEGG） enrichment analysis were used to investigate the effect of MED19 expression on other gene sets. The relationship between MED19 expression level and drug sensitivity was analyzed by Cellminer database data. Results: The expression of MED19 increased in tumor tissues（W=1 422，P<0.001），and the expression level of MED19 was correlated with clinical stage（Stage Ⅱ vs. Stage I: W=5 828，stage Ⅲ vs. Stage Ⅰ，W=5 707， P<0.01），pathological grading（G3 vs. G1: W=2 656，P<0.05） and T staging （T2 vs. T1: W=6 485，P<0.01，T3 vs. T1: W=5 758，P<0.01，T4 vs. T1：W=770，P<0.05）. The expression of MED19 was different in different immune subtypes，and the high expression of MED19 caused the decrease of matrix score（W=14 363，P<0.01）. The high expression of MED19 decreased the survival rate of HCC patients （χ2=11.7，P<0.01） and was an independent risk factor for survival of patients（HR=1.123，P<0.01）. GSEA results showed that the high expression group of MDE19 was enriched in cancer-related pathways. In addition，GO and KEGG analysis of the differential genes screened out from the high expression group and the low expression group of MED19 showed that the up-regulation genes in the high expression group of MED19 were mainly enriched in cell cycle-related pathways. Drug sensitivity analysis showed that the high expression of MED19 in cancer was positively correlated with the sensitivity of clattrobin（r=0.331，t=2.671，P=0.010），chelidonine（r=0.313，t=2.507，P=0.015） and other drugs. Conclusion: The expression of MED19 is elevated in HCC and is associated with poor prognosis of hepatocellular carcinoma.

参考文献/References:

[1] SIEGEL R L，MILLER K D，JEMAL A. Cancer statistics，2020 [J]. CA Cancer J Clin，2020，70（1）：7-30.
[2] ALLEMANI C，WEIR H K，CARREIRA H，et al. Global surveillance of cancer survival 1995-2009：analysis of individual data for 25676887 patients from 279 population-based registries in 67 countries（CONCORD-2）[J]. Lancet，2015，385（9972）：977-1010.
[3] SERPER M，TADDEI T H，MEHTA R，et al. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality[J]. Gastroenterology，2017，152（8）：1954-1964.
[4] WANG H，LU Z，ZHAO X. Tumorigenesis，diagnosis，and therapeutic potential of exosomes in liver cancer [J]. J Hematol Oncol，2019，12（1）：133.
[5] ZHANG Q，LOU Y，BAI X L，et al. Immunometabolism：a novel perspective of liver cancer microenvironment and its influence on tumor progression [J]. World J Gastroenterol，2018，24（31）：3500-3512.
[6] TU S，HUANG W，HUANG C，et al. Contextual regulation of TGF-beta signaling in liver cancer [J]. Cells，2019，8（10）：1235.
[7] SCHIER A C，TAATJES D J. Structure and mechanism of the RNA polymerase Ⅱ transcription machinery[J]. Genes Dev，2020，34（7/8）：465-488.
[8] GUGLIELMI B，VAN BERKUM N L，KLAPHOLZ B，et al. A high resolution protein interaction map of the yeast Mediator complex [J]. Nucleic Acids Res，2004，32（18）：5379-5391.
[9] CONAWAY R C，CONAWAY J W. The Mediator complex and transcription elongation [J]. Biochim Biophys Acta，2013，1829（1）：69-75.
[10] IMMARIGEON C，BERNAT-FABRE S，GUILLOU E，et al. Mediator complex subunit Med19 binds directly GATA transcription factors and is required with Med1 for GATA-driven gene regulation in vivo [J]. J Biol Chem，2020，295（39）：13617-13629.
[11] DEAN J M，HE A，TAN M，et al. MED19 regulates adipogenesis and maintenance of white adipose tissue mass by mediating PPARgamma-dependent gene expression [J]. Cell Rep，2020，33（1）：108228.
[12] ZHANG X，GAO D，FANG K，et al. Med19 is targeted by miR-101-3p/miR-422a and promotes breast cancer progression by regulating the EGFR/MEK/ERK signaling pathway [J]. Cancer Lett，2019，444：105-115.
[13] DING X F，HUANG G M，SHI Y，et al. Med19 promotes gastric cancer progression and cellular growth[J]. Gene，2012，504（2）：262-267.
[14] SUN M，JIANG R，LI J D，et al. MED19 promotes proliferation and tumorigenesis of lung cancer[J]. Mol Cell Biochem，2011，355（1-2）：27-33.
[15] YUAN H，YU S，CUI Y，et al. Knockdown of mediator subunit Med19 suppresses bladder cancer cell proliferation and migration by downregulating Wnt/beta-catenin signalling pathway[J]. J Cell Mol Med，2017，21（12）：3254-3263.
[16] PI?譙ERO F，DIRCHWOLF M，PESS?魺A M G. Biomarkers in hepatocellular carcinoma：diagnosis，prognosis and treatment response assessment [J]. Cells，2020，9（6）:1370.
[17] KUO M T. Redox regulation of multidrug resistance in cancer chemotherapy：molecular mechanisms and therapeutic opportunities [J]. Antioxid Redox Signal，2009，11（1）：99-133.
[18] CLARK T，MAXIMIN S，MEIER J，et al. Hepatocellular carcinoma：review of epidemiology，screening，imaging diagnosis，response assessment，and treatment [J]. Curr Probl Diagn Radiol，2015，44（6）：479-486.
[19] KHAN F S，ALI I，AFRIDI U K，et al. Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics[J]. Hepatol Int，2017，11（1）：45-53.
[20] LEWIS B A，REINBERG D. The mediator coactivator complex：functional and physical roles in transcriptional regulation[J]. J Cell Sci，2003，116（Pt 18）：3667-3675.
[21] WEBER H，RUOFF R，GARABEDIAN M J. MED19 alters AR occupancy and gene expression in prostate cancer cells，driving MAOA expression and growth under low androgen[J]. PLoS Genetics，2021，17（1）：e1008540.
[22] YU W，ZHANG Z，MIN D，et al. Mediator of RNA polymerase Ⅱ transcription subunit 19 promotes osteosarcoma growth and metastasis and associates with prognosis[J]. Eur J Cancer，2014，50（6）：1125-1136.
[23] CHEN L，LIANG Z，TIAN Q，et al. Overexpression of LCMR1 is significantly associated with clinical stage in human NSCLC[J]. J Exp Clin Cancer Res，2011，30：18.
[24] RAMMOHAN K，COYLE P K，SYLVESTER E，et al. The development of cladribine tablets for the treatment of multiple sclerosis：a comprehensive review [J]. Drugs，2020，80（18）：1901-1928.
[25] CHIHARA D，KANTARJIAN H，O'BRIEN S，et al. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia：update of a phase Ⅱ trial [J]. Br J Haematol，2016，174（5）：760-766.
[26] YANG B，ZHANG D，QIAN J，et al. Chelerythrine suppresses proliferation and metastasis of human prostate cancer cells via modulating MMP/TIMP/NF-kappaB system[J]. Mol Cell Biochem，2020，474（1-2）：199-208.
[27] YANG T，XU R，SU Q，et al. Chelerythrine hydrochloride inhibits proliferation and induces mitochondrial apoptosis in cervical cancer cells via PI3K/BAD signaling pathway[J]. Toxicol In Vitro，2020， 68：104965.
[28] OO Z Y，PROCTOR M，STEVENSON A J，et al. Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression，with reduced normal tissue toxicity compared to gemcitabine[J]. Mol Oncol，2019，13（7）：1503-1518.
[29] BROCKSTEIN B，HARAF D J，STENSON K，et al. A phase Ⅰ-Ⅱ study of concomitant chemoradiotherapy with paclitaxel（one-hour infusion），5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer[J]. Ann Oncol，2000，11（6）：721-728.
[30] THOMAS A，POMMIER Y. Targeting topoisomerase Ⅰ in the Era of precision medicine[J]. Clin Cancer Res，2019，25（22）：6581-6589.

相似文献/References:

[1]陈 环.肝癌介入治疗前后α2-抗纤溶酶、抗凝血酶Ⅲ、凝血因子Ⅷ检测的临床意义[J].天津医科大学学报,2014,20(04):327.
[2]廖诗晗,赵秀兰,张艳辉,等.LCMT1在肝癌中的表达和预后的意义[J].天津医科大学学报,2019,25(03):246.
　LIAO Shi-han,ZHAO Xiu-lan,ZHANG Yan-hui,et al.The expression and prognostic significance of LCMT1 in hepatocellular carcinoma[J].Journal of Tianjin Medical University,2019,25(04):246.
[3]张丽梅,贾莉莉 综 述,喻文立 审 校.外泌体在病毒性肝炎、肝硬化和肝癌中的作用研究进展[J].天津医科大学学报,2019,25(03):305.
[4]胡善雷,李广明,任 娜,等.GP73在HBV相关性肝病中的水平及意义[J].天津医科大学学报,2019,25(06):615.
　HU Shan-lei,LI Guang-ming,REN Na,et al.The level and significance of GP73 in HBV related liver diseases[J].Journal of Tianjin Medical University,2019,25(04):615.
[5]陈莹,张雅敏.围手术期肠内、外营养治疗在肝切除术后患者快速康复中的作用[J].天津医科大学学报,2021,27(04):384.
　CHEN Ying,ZHANG Ya-min.Effect of perioperative enteral and parenteral nutrition on rapid recovery of patients after hepatectomy[J].Journal of Tianjin Medical University,2021,27(04):384.
[6]谢永丽,汤华.YTHDF1对HBV蛋白表达和HBsAg和HBeAg抗原分泌的作用[J].天津医科大学学报,2021,27(05):461.
　XIE Yong-li,TANG Hua.Role of YTHDF1 on HBV protein expression and secretion of HBsAg and HBeAg antigens[J].Journal of Tianjin Medical University,2021,27(04):461.
[7]闫墨,刘帅兵,王楷斌,等.基于生物信息学方法筛选精原细胞瘤进展中的脂代谢关键基因[J].天津医科大学学报,2022,28(06):585.
　YAN Mo,LIU Shuai-bing,WANG Kai-bin,et al.Identification of key lipid metabolism genes in the progress of seminoma by integrated bioinformatics analysis[J].Journal of Tianjin Medical University,2022,28(04):585.
[8]罗焱瑞,赵倩.基于多组学Lasso回归分析构建肝癌预测模型[J].天津医科大学学报,2024,30(03):205.[doi:10.20135/j.issn.1006-8147.2024.03.0205]
　LUO Yanrui,ZHAO Qian.A liver cancer prediction model based on multi-omics Lasso regression analysis[J].Journal of Tianjin Medical University,2024,30(04):205.[doi:10.20135/j.issn.1006-8147.2024.03.0205]
[9]赵冉,武燕洁,刘振凤,等.基于TCGA数据库分析JMJD6在肝癌组织中的表达及临床意义[J].天津医科大学学报,2022,28(01):15.
　ZHAO Ran,WU Yan-jie,LIU Zhen-feng,et al.The expression and clinical significance of JMJD6 in hepatocellular carcinoma based on TCGA database[J].Journal of Tianjin Medical University,2022,28(04):15.

备注/Memo

备注/Memo:

作者简介:武燕洁（1996-），女，硕士在读，研究方向：肿瘤表观遗传学；通信作者：宣成昊，E-mail：chenghaoxuan@tmu.edu.cn；兰蓓，E-mail：lanpei@tmu.edu.cn。

常用功能

更新日期/Last Update: 2022-07-20